Therapeutic and diagnostic implications of Hsp90 activation

  • Kamal A
  • Boehm M
  • Burrows F
  • 60

    Readers

    Mendeley users who have this article in their library.
  • 208

    Citations

    Citations of this article.

Abstract

The molecular chaperone heat-shock protein 90 (Hsp90) is involved in the stabilization and conformational maturation of many signaling proteins that are deregulated in cancers. Hsp90 inhibition results in the proteasomal degradation of these client proteins and leads to potent antitumor activity. The Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG) is presently in clinical trials. Recent work has identified the role of Hsp90 in multiple signal transduction pathways and revealed that the molecular mechanism of tumor selectivity by Hsp90 inhibitors is the result of an activated, high-affinity conformation of Hsp90 in tumors. This review discusses these recent advances in the understanding of tumor Hsp90 for the treatment and diagnosis of cancer. In addition, the role of Hsp90 in non-oncological diseases will also be discussed.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Adeela Kamal

  • Marcus F. Boehm

  • Francis J. Burrows

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free